Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Accured Expenses (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Change in Accured Expenses data on record, last reported at $85000.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 140.48% year-over-year to $85000.0; the TTM value through Sep 2025 reached $27000.0, up 103.21%, while the annual FY2024 figure was -$515000.0, 67.49% up from the prior year.
  • Change in Accured Expenses reached $85000.0 in Q3 2025 per CYCN's latest filing, up from -$138000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $462000.0 in Q2 2023 and bottomed at -$3.4 million in Q1 2021.
  • Average Change in Accured Expenses over 5 years is -$362526.3, with a median of -$186000.0 recorded in 2022.
  • The widest YoY moves for Change in Accured Expenses: up 527.78% in 2023, down 636.36% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$281000.0 in 2021, then soared by 33.81% to -$186000.0 in 2022, then plummeted by 97.31% to -$367000.0 in 2023, then skyrocketed by 88.83% to -$41000.0 in 2024, then surged by 307.32% to $85000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $85000.0 in Q3 2025, -$138000.0 in Q2 2025, and $121000.0 in Q1 2025.